Swiss drugmaker Roche Holding AG said on Thursday it would buy the rest of U.S. cancer data company Flatiron Health for $1.9 billion to speed development of cancer medicines and support its efforts to price them based on how well they work.
Privately held Flatiron, backed by Alphabet Inc, taps into data on individual cancer cases to help doctors select promising approaches for their patients.
It also stores billing data, doctors’ notes and related information.
Roche currently owns 12.6 percent of Flatiron.
In 2016, Roche led a $175 million investment into Flatiron, in part to help the Swiss company harness the deluge of still-underutilized data collected from cancer patients with the New York City-based company’s products.
Roche has said Flatiron algorithms will improve not only its research and trials, but also buttress its arguments during head-to-head price talks with payers as new combinations of its expensive therapies hit the market.
“It gives us better insights into the potential for our products,” Roche’s head of pricing Jens Grueger told Reuters in a 2016 interview.
“But it also creates flexibility in how we can create value contracts in the future.”
Roche has made a number of bolt-on acquisitions in recent months, including in December when it said it would buy U.S. cancer drug specialist Ignyta Inc for $1.7 billion in a deal to broaden its oncology portfolio.
In 2014, Google Ventures led a $130 million investment in Flatiron as healthcare had become a hot area for venture capital, especially companies related to health, data and software.
Roche and Flatiron expect the deal to close in the first half of 2018, after which the latter will continue its operations as a separate entity.
Allen & Company LLC is the financial adviser to Flatiron Health and Wilson Sonsini Goodrich & Rosati is its legal counsel. Davis Polk & Wardwell LLP is acting as legal counsel to Roche.
By Akankshita Mukhopadhyay and John Miller
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.
Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.
Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.